Evaluation of 0.3% Motugivatrep Ophthalmic Suspension on Visual Function and Soft Contact Lens in Patients with Dry Eye

Evaluation of 0.3% Motugivatrep Ophthalmic Suspension on Visual Function and Soft Contact Lens in Patients with Dry Eye - Evaluation of 0.3% Motugivatrep Ophthalmic Suspension on Visual Function and Soft Contact Lens in Patients with Dry Eye

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061171

Enrollment

Registered

2026-04-06

Start date

2026-04-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia / Dry Eye

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients aged 18 to 40 at consenting 2.Patients capable of providing written informed consent by their own free will 3.Patients who meet the diagnostic criteria for dry eye (BUT: 5 seconds or less, with subjective symptoms) and have been prescribed ophthalmic Motugibatrep suspension during routine medical care 4.Patients who routinely wear bi-weekly replacement SCLs (spherical) in both eyes (6 hours or more per day, 5 days or more per week) 5.Patients with visual acuity of 0.8 or higher while wearing SCLs 6.Patients capable of properly performing SCL care, such as cleaning 7.Patients whom the physician judges can be appropriately evaluated for the efficacy and safety of this study

Exclusion criteria

Exclusion criteria: 1.Patients wearing multifocal or astigmatism-correcting SCLs 2.Patients wearing colored SCLs 3.Patients who have used other dry eye medications* within 14 days before consenting *Patients who have used artificial tears can be registered. 4.Patients with corneal erosions requiring treatment, or patients with punctal plugs inserted 5.Individuals requiring a legal representative 6.Individuals with other conditions that the responsible investigator or subinvestigator deemed unsuitable for participation in the study

Design outcomes

Primary

Measure	Time frame
Mean change in visual acuity from baseline to week 4 after initiation of wearing SCLs	—

Secondary

Measure	Time frame
1.Mean change in contrast sensitivity from baseline to week 4 2.Mean change in the DEQS symptom score (6 items) from baseline to week 4 3.Mean change in the J-CLDEQ-8 from baseline to week 4 4.Mean change in BUT from baseline to week 4 5.Mean change in corneal staining score using National Eye Institute (NEI)/Industry Workshop grading scale from baseline to week 4 6.Mean change in conjunctival staining score using van Bijsterveld score from baseline to week 4 7.Physical properties of SCLs at week 2 (compared to unused lenses) 1)Shape and appearance 2)Diameter 3)Base curve 4)Vertex power 5)Thickness 6)Optical transmittance 7)Water content 8.Frequency and severity of each adverse event	—

Measure

Time frame

1.Mean change in contrast sensitivity from baseline to week 4 2.Mean change in the DEQS symptom score (6 items) from baseline to week 4 3.Mean change in the J-CLDEQ-8 from baseline to week 4 4.Mean change in BUT from baseline to week 4 5.Mean change in corneal staining score using National Eye Institute (NEI)/Industry Workshop grading scale from baseline to week 4 6.Mean change in conjunctival staining score using van Bijsterveld score from baseline to week 4 7.Physical properties of SCLs at week 2 (compared to unused lenses) 1)Shape and appearance 2)Diameter 3)Base curve 4)Vertex power 5)Thickness 6)Optical transmittance 7)Water content 8.Frequency and severity of each adverse event

—

Countries

Japan

Contacts

Public ContactKoh Shizuka

Yukoukai General Hospital Ophthalmology

cizciz@gmail.com072-641-2488

Outcome results